209 related articles for article (PubMed ID: 25238142)
1. Loss of Trop2 causes ErbB3 activation through a neuregulin-1-dependent mechanism in the mesenchymal subtype of HNSCC.
Zhang K; Jones L; Lim S; Maher CA; Adkins D; Lewis J; Kimple RJ; Fertig EJ; Chung CH; Van Tine BA; Ellis MJ; Herrlich A; Michel LS
Oncotarget; 2014 Oct; 5(19):9281-94. PubMed ID: 25238142
[TBL] [Abstract][Full Text] [Related]
2. Anti-Trop2 blockade enhances the therapeutic efficacy of ErbB3 inhibition in head and neck squamous cell carcinoma.
Redlich N; Robinson AM; Nickel KP; Stein AP; Wheeler DL; Adkins DR; Uppaluri R; Kimple RJ; Van Tine BA; Michel LS
Cell Death Dis; 2018 Jan; 9(1):5. PubMed ID: 29305574
[TBL] [Abstract][Full Text] [Related]
3. ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC.
Alvarado D; Ligon GF; Lillquist JS; Seibel SB; Wallweber G; Neumeister VM; Rimm DL; McMahon G; LaVallee TM
PLoS One; 2017; 12(7):e0181356. PubMed ID: 28723928
[TBL] [Abstract][Full Text] [Related]
4. Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients.
Duvvuri U; George J; Kim S; Alvarado D; Neumeister VM; Chenna A; Gedrich R; Hawthorne T; LaVallee T; Grandis JR; Bauman JE
Clin Cancer Res; 2019 Oct; 25(19):5752-5758. PubMed ID: 31308059
[TBL] [Abstract][Full Text] [Related]
5. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
[TBL] [Abstract][Full Text] [Related]
6. [Effect of human trophoblast cell-surface antigen 2 gene expression by RNA interference on proliferation and apoptosis of tongue squamous cell carcinoma and its mechanism].
Fang Z; Chen S; Zhao JF; Sun Q; Qiu F; Li XM
Zhonghua Kou Qiang Yi Xue Za Zhi; 2018 Sep; 53(9):640-644. PubMed ID: 30196628
[No Abstract] [Full Text] [Related]
7. ERBB3/HER2 signaling promotes resistance to EGFR blockade in head and neck and colorectal cancer models.
Zhang L; Castanaro C; Luan B; Yang K; Fan L; Fairhurst JL; Rafique A; Potocky TB; Shan J; Delfino FJ; Shi E; Huang T; Martin JH; Chen G; Macdonald D; Rudge JS; Thurston G; Daly C
Mol Cancer Ther; 2014 May; 13(5):1345-55. PubMed ID: 24634416
[TBL] [Abstract][Full Text] [Related]
8. Neuregulin Signaling Is a Mechanism of Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma.
Baro M; Lopez Sambrooks C; Burtness BA; Lemmon MA; Contessa JN
Mol Cancer Ther; 2019 Nov; 18(11):2124-2134. PubMed ID: 31387891
[TBL] [Abstract][Full Text] [Related]
9. Loss of Trop2 promotes carcinogenesis and features of epithelial to mesenchymal transition in squamous cell carcinoma.
Wang J; Zhang K; Grabowska D; Li A; Dong Y; Day R; Humphrey P; Lewis J; Kladney RD; Arbeit JM; Weber JD; Chung CH; Michel LS
Mol Cancer Res; 2011 Dec; 9(12):1686-95. PubMed ID: 21970857
[TBL] [Abstract][Full Text] [Related]
10. SATB1 as oncogenic driver and potential therapeutic target in head & neck squamous cell carcinoma (HNSCC).
Panchal O; Wichmann G; Grenman R; Eckhardt L; Kunz-Schughart LA; Franke H; Dietz A; Aigner A
Sci Rep; 2020 May; 10(1):8615. PubMed ID: 32451408
[TBL] [Abstract][Full Text] [Related]
11. TROP2 increases growth and metastasis of human oral squamous cell carcinoma through activation of the PI3K/Akt signaling pathway.
Tang G; Tang Q; Jia L; Chen Y; Lin L; Kuai X; Gong A; Feng Z
Int J Mol Med; 2019 Dec; 44(6):2161-2170. PubMed ID: 31638186
[TBL] [Abstract][Full Text] [Related]
12. P2Y2 nucleotide receptors mediate metalloprotease-dependent phosphorylation of epidermal growth factor receptor and ErbB3 in human salivary gland cells.
Ratchford AM; Baker OJ; Camden JM; Rikka S; Petris MJ; Seye CI; Erb L; Weisman GA
J Biol Chem; 2010 Mar; 285(10):7545-55. PubMed ID: 20064929
[TBL] [Abstract][Full Text] [Related]
13. Loss of miR-125b-1 contributes to head and neck cancer development by dysregulating TACSTD2 and MAPK pathway.
Nakanishi H; Taccioli C; Palatini J; Fernandez-Cymering C; Cui R; Kim T; Volinia S; Croce CM
Oncogene; 2014 Feb; 33(6):702-12. PubMed ID: 23416980
[TBL] [Abstract][Full Text] [Related]
14. Lyn kinase mediates cell motility and tumor growth in EGFRvIII-expressing head and neck cancer.
Wheeler SE; Morariu EM; Bednash JS; Otte CG; Seethala RR; Chiosea SI; Grandis JR
Clin Cancer Res; 2012 May; 18(10):2850-60. PubMed ID: 22490227
[TBL] [Abstract][Full Text] [Related]
15. Trop2 inhibition suppresses the proliferation and invasion of laryngeal carcinoma cells via the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway.
Wang XD; Wang Q; Chen XL; Huang JF; Yin Y; Da P; Wu H
Mol Med Rep; 2015 Jul; 12(1):865-70. PubMed ID: 25779928
[TBL] [Abstract][Full Text] [Related]
16. Neuregulin/erythroblastic leukemia viral oncogene homolog 3 autocrine loop contributes to invasion and early recurrence of human hepatoma.
Hsieh SY; He JR; Hsu CY; Chen WJ; Bera R; Lin KY; Shih TC; Yu MC; Lin YJ; Chang CJ; Weng WH; Huang SF
Hepatology; 2011 Feb; 53(2):504-16. PubMed ID: 21246584
[TBL] [Abstract][Full Text] [Related]
17. Potential therapeutic target and independent prognostic marker of TROP2 in laryngeal squamous cell carcinoma.
Wu H; Xu H; Zhang S; Wang X; Zhu H; Zhang H; Zhu J; Huang J
Head Neck; 2013 Oct; 35(10):1373-8. PubMed ID: 22987366
[TBL] [Abstract][Full Text] [Related]
18. Dysregulation of junctional adhesion molecule-A via p63/GATA-3 in head and neck squamous cell carcinoma.
Kakuki T; Kurose M; Takano K; Kondoh A; Obata K; Nomura K; Miyata R; Kaneko Y; Konno T; Takahashi S; Hatakeyama T; Kohno T; Himi T; Kojima T
Oncotarget; 2016 Jun; 7(23):33887-900. PubMed ID: 27036044
[TBL] [Abstract][Full Text] [Related]
19. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
[TBL] [Abstract][Full Text] [Related]
20. HRG-β1-driven ErbB3 signaling induces epithelial-mesenchymal transition in breast cancer cells.
Kim J; Jeong H; Lee Y; Kim C; Kim H; Kim A
BMC Cancer; 2013 Aug; 13():383. PubMed ID: 23937725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
